One of our goals as an organization is to bridge the drug development gap and bring promising therapies to the next level of funding. A terrific example of this goal in action is Celgene’s recent purchase of LLS partner, Avila Theraputics.
LLS recognized the potential in Avila’s protein silencing therapy to treat B-cell cancers back in 2010 and helped bring a molecule called AVL-292 to Phase 1 clinical trials. LLS’s early investment allowed Avila to quickly advance the molecule. Now with the drug in Celgene’s very capable hands, there is high confidence that its full potential will be unlocked.
All too often research advances are inhibited by a lack of funding. In the case of Avila, LLS was able to financially bridge the gap and set AVL-292 on the track to success. Now the brilliant minds at Celgene can work their magic and help this train reach its destination and deliver a new therapy to patients.